Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology -February 21, 2024 at 09:03 am EST

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety...

Related Keywords

United States ,Canada ,United Kingdom ,Germany ,German ,America , ,Catalyst Or Company Nasdaq ,Catalyst Pharmaceuticals Inc ,Life Science Alliance ,Exchange Commission ,Catalyst Pharmaceuticals ,Health Canada ,Study Reports ,Week Treatment ,Duchenne Muscular Dystrophy ,Safety Profile ,Santhera Pharmaceutical ,Vamorolone Over ,Boys With Duchenne Muscular ,North Star Ambulatory Assessment ,Orphan Drug ,Rare Pediatric Disease ,Promising Innovative Medicine ,Proc Natl Acad Sci United States ,Product Characteristics ,North America ,Duchenne Muscular ,Fast Track ,Full Prescribing ,Safety Information ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,